SC 13G/A: PFIZER INC
Ticker: PFE · Form: SC 13G/A · Filed: 2024-03-15T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by PFIZER INC.
Risk Assessment
Risk Level: low
From the Filing
0000078003-24-000075.txt : 20240315 0000078003-24-000075.hdr.sgml : 20240315 20240315074513 ACCESSION NUMBER: 0000078003-24-000075 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Tourmaline Bio, Inc. CENTRAL INDEX KEY: 0001827506 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92543 FILM NUMBER: 24752492 BUSINESS ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 646-481-9832 MAIL ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Talaris Therapeutics, Inc. DATE OF NAME CHANGE: 20201007 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 SC 13G/A 1 tourmalinebioschedule13ga3.htm SC 13G/A 1 TOURMALINE BIO Document   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   SCHEDULE 13G   UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing)* TOURMALINE BIO, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89157D 105 (CUSIP Number) January 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |X| Rule 13d-1(c) |_| Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).       Page 1 of 5 CUSIP No. 89157D 105   1. Names of Reporting Persons. PFIZER INC. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐   3. SEC Use Only 4. Citizenship or Place of Organization: Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. Sole Voting Power: 1,272,214 shares of common stock, $0.0001 par value per share (“Common Stock”) 6. Shared Voting Power: -0- 7. Sole Dispositive Power: 1,272,214 shares of Common Stock 8. Shared Dispositive Power: -0- 9. Aggregate Amount Beneficially Owned by Reporting Person: 1,272,214 shares of Common Stock are beneficially owned by Pfizer Inc. 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9): 4.96% (1) 12. Type of Reporting Person (See Instructions): CO   (1) This percentage is calculated based on 25,645,262 shares of Common Stock outstanding, as disclosed by the Issuer in its prospectus supplement dated January 25, 2024 and filed with the Securities